Opthocare XT (Dorzolamide Hydrochloride 2% + Timolol Maleate 0.5%) is a combination ophthalmic solution designed for effective control of intraocular pressure (IOP) in patients with glaucoma. By combining the carbonic anhydrase inhibitor Dorzolamide and the beta-blocker Timolol, Opthocare XT works synergistically to reduce IOP, helping prevent damage to the optic nerve. It is ideal for managing early-stage glaucoma, effectively controlling IOP levels within the following ranges: 10-25 mm Hg (normal), 25-30 mm Hg (mild), 30-40 mm Hg (moderate), and 40 mm Hg and above (severe). This dual-action formula ensures better glaucoma management and improved ocular health.
0-25 (mm Hg) Normal
25-30 (mm Hg) Mild
30-40 (mm Hg) Moderate
40 & above (mm Hg) Severe
Opthocare XT is offered in a single, highly effective combination formulation of Dorzolamide Hydrochloride 2% and Timolol Maleate 0.5%. This dual-action solution addresses glaucoma's underlying causes by both reducing aqueous humor production (via Dorzolamide) and improving fluid outflow (via Timolol), making it a comprehensive treatment for early glaucoma control. The single variation simplifies treatment, ensuring precise dosing and consistent results, while offering a targeted approach that effectively manages intraocular pressure across a wide range of IOP levels, making it the best choice for glaucoma patients in the early stages.
Opthocare XT combines two powerful agents: Dorzolamide, a carbonic anhydrase inhibitor that reduces aqueous humor production, and Timolol, a beta-blocker that decreases fluid production and increases outflow. This dual mechanism effectively reduces intraocular pressure (IOP), making it highly efficient in controlling glaucoma.
Opthocare XT is designed to manage IOP across a broad range, from normal (10-25 mm Hg) to severe (40 mm Hg and above). Its unique formulation offers tailored pressure reduction for patients at varying stages of glaucoma, ensuring consistent and reliable results for both mild and severe cases.
The combination of Dorzolamide and Timolol provides a synergistic effect, improving patient outcomes in glaucoma treatment. This allows for better long-term control of IOP and reduced risk of optic nerve damage, ultimately preserving vision and eye health in patients with early glaucoma.
Q
What is Opthocare XT used for?
A
Opthocare XT is an ophthalmic solution used for the management of early glaucoma. It helps control intraocular pressure (IOP) by reducing the production of aqueous humor and improving fluid outflow, preventing optic nerve damage.
Q
How does Opthocare XT work?
A
Opthocare XT combines two active ingredients: Dorzolamide, which reduces aqueous humor production, and Timolol, which improves fluid outflow. This dual-action formulation effectively reduces intraocular pressure, helping to control glaucoma.
Q
When should I use Opthocare XT?
A
Opthocare XT is recommended for patients with elevated intraocular pressure (IOP) due to early-stage glaucoma. It is effective for managing IOP levels in the normal to severe range, ensuring better control over the condition.
